Gadolinium in pediatric cardiovascular magnetic resonance: What we know and how we practice

Journal of Cardiovascular Magnetic Resonance

Volumn 14, Issue 1, 2012, Pages

  Meng, Howard ^a   Grosse Wortmann, Lars ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE;

ADOLESCENT; ANAPHYLAXIS; ARTICLE; AWARENESS; BRONCHOSPASM; CARDIAC IMAGING; CHILD; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DRUG INDUCED HEADACHE; GLOMERULUS FILTRATION RATE; HEALTH SURVEY; HUMAN; INFANT; INJECTION SITE REACTION; KIDNEY FUNCTION; LICENCE; MEDICAL SPECIALIST; NAUSEA; NEPHROGENIC SYSTEMIC FIBROSIS; NEWBORN; NEWBORN PERIOD; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; VOMITING; WORK ENVIRONMENT;

ADOLESCENT; AGE FACTORS; BENCHMARKING; CHILD; CHILD, PRESCHOOL; CONTRAST MEDIA; GADOLINIUM; GADOLINIUM DTPA; GLOMERULAR FILTRATION RATE; HEALTH CARE SURVEYS; HUMANS; INFANT; INFANT, NEWBORN; KIDNEY; MAGNETIC RESONANCE IMAGING; MEGLUMINE; NEPHROGENIC FIBROSING DERMOPATHY; ORGANOMETALLIC COMPOUNDS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS;

EID: 84864742618     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-14-56     Document Type: Article

References (24)

1. CR Committee on Drugs and Contrast Media [Internet] 2010 http://www.acr.org/secondarymainmenucategories/quality-safety/contrast-manual. aspx.
2. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. Hunt CH, Hartman RP, Hesley GK, AJR Am J Roentgenol 2009 193 4 1124 1127 10.2214/AJR.09.2520 19770337
3. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance. Voth M, Rosenberg M, Breuer J, Invest Radiol 2011 46 11 663 671 21623211
4. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients. Hahn G, Sorge I, Gruhn B, Glutig K, Hirsch W, Bhargava R, Furtner J, Born M, Schroder C, Ahlstrom H, Kaiser S, Moritz JD, Kunze CW, Schroff M, Stokland E, Trnkova ZJ, Schultze-Mosgau M, Reif S, Bacher-Stier C, Mentzel HJ, Invest Radiol 2009 44 12 776 783 10.1097/RLI.0b013e3181bfe2d2 19858730
5. The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients. Lowe L, Kearns G, Wible J, Curr Med Res Opin 2006 22 12 2515 2524 10.1185/030079906X159452 17166334 (Pubitemid 46048367)
6. Safety and efficacy of Omniscan (gadodiamide injection) at 0.1 mmol/kg for MRI in intants younger than 6 months of age: phase III open multicenter study. Marti-Bonmati L, Vega T, Benito C, Munoz A, Niewei M, Menor F, Neurer K, Encina JL, Invest Radiol 2000 35 2 141 147 10.1097/00004424-200002000-00008 10674459 (Pubitemid 30078275)
7. Prevalence of acute adverse reactions to gadobutrolA highly concentrated macrocyclic gadolinium chelate: Review of 14,299 patients from observational trials. Forsting M, Palkowitsch P, Eur J Radiol 2010 74 3 186 e192 10.1016/j.ejrad.2009.06.005 19574008
8. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Perazella MA, Curr Drug Saf 2008 3 1 67 75 10.2174/157488608783333989 18690983 (Pubitemid 351223155)
9. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Cowper SE, Am J Kidney Dis 2005 46 4 763 765 10.1053/j.ajkd.2005.08.008 16183434 (Pubitemid 41383957)
10. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Grobner T, Nephrol Dial Transplant 2006 21 4 1104 1108 16431890
11. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C, Fundam Clin Pharmacol 2006 20 6 563 576 10.1111/j.1472-8206.2006.00447.x 17109649 (Pubitemid 44760175)
12. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Wermuth PJ, Del Galdo F, Jimenez SA, Arthritis Rheum 2009 60 5 1508 1518 10.1002/art.24471 19404939
13. Questions and answers on the review of gadolinium-containing contrast agents [Internet]. Euro Med Agency 2010 http://www.ema.europa.eu/docs/en/ gadolinium/WC500015635.pdf
14. Gadolinium and nephrogenic systemic fibrosis - what to consider for pediatric MR imaging. Riccabona M, Dacher JN, Olsen E, Claudon M, Fotter R, Pediatric Uroradiology Springer, Fotter R, Baert AL, 2 2008 516 517
15. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Deo A, Fogel M, Cowper SE, Clin J Am Soc Nephrol 2007 2 2 264 267 10.2215/CJN.03921106 17699423
16. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH, Radiology 2011 260 1 105 111 10.1148/radiol.11102340 21586680
17. MR contrast agents, the old and the new. Bellin MF, Eur J Radiol 2006 60 3 314 323 10.1016/j.ejrad.2006.06.021 17005349
18. High-spatial-resolution multistation MR angiography with parallel imaging and blood pool contrast agent: initial experience. Nikolaou K, Kramer H, Grosse C, Clevert D, Dietrich O, Hartmann M, Chamberlin P, Assmann S, Reiser MF, Schoenberg SO, Radiology 2006 241 3 861 872 10.1148/radiol.2413060053 17032914 (Pubitemid 46190554)
19. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Swan SK, Lambrecht LJ, Townsend R, Davies BE, McCloud S, Parker JR, Bensel K, LaFrance ND, Invest Radiol 1999 34 7 443 448 10.1097/00004424-199907000-00001 10399633 (Pubitemid 29302836)
20. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy - report from two U.S. universities. Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER, Semelka RC, Radiology 2009 253 3 689 696 10.1148/radiol.2533090649 19789233
21. Reference values for serum creatinine in children younger than 1 year of age. Boer DP, de Rijke YB, Hop WC, Cransberg K, Dorresteijn EM, Pediatr Nephrol 2010 25 10 2107 2113 10.1007/s00467-010-1533-y 20505955
22. CAR national advisory on gadolinium administration and nephrogenic systemic fibrosis [Internet] 2008 http://www.car.ca/uploads/standards guidelines/advisory-nsf-en.pdf.
23. Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Filler G, Lepage N, Pediatr Nephrol 2003 18 10 981 985 10.1007/s00467-003-1271-5 12920638 (Pubitemid 37236209)
24. How to estimate GFR in children. Delanghe JR, Nephrol Dial Transplant 2009 24 3 714 716 18515653